Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety and Efficacy of CD19-Targeted Universal CAR-γδ T Cells in Relapsed/Refractory Autoimmune Nephropathy

NCT07535138 is registered in ClinicalTrials.gov with Air Force Military Medical University, China as lead sponsor.

NCT NCT07535138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07535138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety and Efficacy of CD19-Targeted Universal CAR-γδ T Cells in Relapsed/Refractory Autoimmune Nephropathy
Lead sponsor
Air Force Military Medical University, China
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
December 30, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy (igan), lupus nephritis (ln), membranous nephropathy